Artemisinin: An alternative treatment for oral squamous cell carcinoma

Eiki Yamachika, Temesgen Habte, Dolphine Oda

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Artemisinin (AR) is a widely used antimalarial drug. Recently, additional uses for AR as an anticancer drug were discovered. Using TUNEL, immunohistochemistry (IHS) markers and flow cytometry techniques, we evaluated the effect of AR and 5-FU on HPV 16 immortalized and transformed human gingival epithelial (IHGK) cells. The results of TUNEL showed that AR-treated IHGK cells consisted of 82% positive cells, while 5-FU-treated cells consisted of 18% positive cells. The IHS markers demonstrated positive staining with Bax, p53, CD40 and CD40L in AR-treated cells and negative staining with Bcl-2. 5-FU-treated cells demonstrated a profile similar to AR but with less intensity. Cell cycle by flow cytometry results showed that only 5-FU-treated cells demonstrated a significant S-phase rate increase to 45%. In conclusion, our results indicate that AR is cytotoxic to transformed oral epithelial cells through apoptosis, while 5-FU is cytotoxic primarily through cell toxicity.

Original languageEnglish
Pages (from-to)2153-2160
Number of pages8
JournalAnticancer research
Volume24
Issue number4
Publication statusPublished - Jul 2004

Keywords

  • Artemisinin
  • Oral squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Artemisinin: An alternative treatment for oral squamous cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Yamachika, E., Habte, T., & Oda, D. (2004). Artemisinin: An alternative treatment for oral squamous cell carcinoma. Anticancer research, 24(4), 2153-2160.